Phase I Trial of Dasatinib, Lenalidomide, and Temozolomide in Children with Relapsed or Refractory Central Nervous System Tumors

BACKGROUND: Single agent studies targeting the tumor microenvironment in central nervous system (CNS) tumors have largely been disappointing. Combination therapies targeting various pathways and cell types may be a more effective strategy. In this phase I study, we evaluated the combination of dasat...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Neurooncol
Главные авторы: Robison, Nathan J., Yeo, Kee Kiat, Berliner, Adrian P., Malvar, Jemily, Sheard, Michael A., Margol, Ashley S., Seeger, Robert C., Rushing, Teresa, Finlay, Jonathan L., Sposto, Richard, Dhall, Girish
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5930136/
https://ncbi.nlm.nih.gov/pubmed/29427149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2791-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы